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D 4.10 Infrainguinal Disease-Preferred Therapeutic Options
Hunink et a11,2 performed key decision and cost-effectiveness studies on femoropopliteal dis-
ease, by using a range ofvalucs found in the literature and performing multiway sensitivity
analyses. In their 1995 study, data were included from 26 selected studies published after 1985,
involving 4,800 PTA procedures and 4,511 surgical bypasses. Quality-adjusted life-years
(QALY) were used as the main effectiveness measure. The pooled 5-year PTA patency results
were calculated for subgroups by lesion type (stenosis vs occlusion) and indication (disabling
claudication vs chronic critical limb ischemia); surgical bypass subgroups were based on indica-
tion, conduit type, and distal anastomosis site (AK./BK).1 Notably, the potential covariates of
lesion length and calf runoff were not analyzed, in part because of the inadequate data descrip-
tors provided in the original reports. (The authors noted that because there was a statistically
significant association between poor runoff and eLI in an earlier paper, 2 either model could be
used.) Stenting or other adjunctive techniques were not considered. This group concluded that
for fernoropopliteal stenosis and CLI, PTA should be the first treatment modality, but for
femoropopliteal occlusions and CLI, surgical bypass is preferable.
Pertinent to the recommendation to attempt PTA first in anatomically favorable lesions, Wilson
et al3 found that for 100 femoropopliteal artery lesions, a failed PTA did not place the patient at
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Figure 25: Average results for surgical treatment.
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higher risk for limb loss or surgical failure. The mortality rate was 2.4% in the surgical group
and 0% in the PTA group. However, the predominant presenting symptom in this study was
intermittent claudication, and the results were not stratified by presenting indication.
Furthermore, this study has been criticized because of its high degree of selectivity, high initial
PTA technical failure rate, and the use of prosthetic conduit in many patients. Nevertheless, it
did suggest that PTA and surgery do have comparable results for a minority subset selected for
anatomic criteria suitable for PTA.
The same general considerations apply as were discussed in the overall strategy of the treatment
of aortoiliac lesions, and the same system will be used for making recommendations. The fol-
lowing recommendations apply to the choice between endovascular and open surgical interven-
tion for CLI. They basically identify categorical levels of increasing lesion severity in which the
choice of intervention shifts progressively from endovascular to open surgical intervention.
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Recommendation 34: Morpholooical stratification offemoropopliteallesions
TASC Type A iliac lesions:
1. Single stenosis <3 em of the CIA or EIA (unilateraljbilateral)
TASC Type B iliac lesions:
2. Single stenosis 3-10 em in length, not involving the distal popliteal artery"
3. Heavily calcified stenoses up to 3 em in length
4. Multiple lesions, each lessthan 3 cm (stenoses or occlusions)
.5. Single or mJsltiple lesions in the absence of continuous tibial runoff to improve inflow for distal
S1J.rgical bypass
TASC Type C femoropopliteallesions:
6. Single stenosis or occlusion longer than 5 em ,.
7. Multiple stenoses 0" occlusions, each 3-5 em, with or without heavy calcificatio,~
TASC Type D femoropopliteallesions:
8. Complete common femoral artery or superficial femoral artery occlusions or complete
popliteal and proximal trifurcatian occlusions.
'CIRSE agreesexcept for thef olloIJ,jng changcs:
TypeB fcmoropopliteal lesions:
2. Single stenoses occlusions3-1 0 cm long, not involJ1iug the distal popliteal 41'1:ery
Type C femoropopliteal lesions:
6. Single stenoses 01' occlusion >10 cm long
R eason tOr dissenting opinion' The lower 10'lg-tC1<tn clinical SIICCess rate oflongSteJlOJtJ and occlusions in earlierstl/die. wasdne to a
loll'technical success rate. However,developments of catheters and wiresbfll'e improJ'cd thetechnical SIICCCSS rate, to befollolPed by
higher patencyrates.J5,36 Studiescomparing PTA with bypass surge7'Y i71ftmoropoplitcal lesions 4--10 em WilD do notexist;
R epeatedfrom p 8104
Recommendation 35: Treatment ofehoice for TASC ~pe A and D femoropopliteal lesions
Endovascular procedure is the treatment of choice for type A lesions, and surgery is the procedure of choice for type
D lesions.
R epeatedfrom p S107
Recommendation 36: Femoropopliteal stenting in PAD
Femoropopliteal stenting as a primR-ry approach to the interventional treatment of intermittent claudication
or CLI is not indictJted. However, stents may have a limited role in salvage ofacute PTAfailures or complica-
tions.
Repeatedfrom p 898
Critical Issue 10: TretJtment of TASC tJ!.pe B R-nd C lesions
More evidence is needed to mR-ke any firm recommendations abo'tt the besttreatment for types Blind C
lesions. ,.
"CIRSE dissenting opinion:
Currentiy endovascuiar treatment ismore commonly IlSedfor type Band C lesions, but moreevidence isneededto make any fi rm rec-
ommendations about best trcatm eut.
Rmson for disswti1/f( oph/iQn: Du e to technical depelopmmts, type C lesions of iliac rindfemoral arteries can be treatedbyendovascu-
lar means with II reasonable technicalsuccess rate (for references, sc« B 4.3) . Therefore, CIRSE believes that in tlinicnlpracticethese
lesionsar« more commonlytreated byendovasculartecbniqncs, althol/gb scientificevidence of fllly superiority ope,' vascular S1l1;gCl')' is
lacking.
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Recommendation 93: Morphological stratification of infrapopliteallesions
TAse Type A infrapopliteal lesions:
1. Single stenoses shorter than 1 em in the tibial or peroneal vessels
TASe Type B infrapopliteal lesions:
2. Multiple focal stenoses of the tibial or peroneal vessel, each less than 1 em in length
3. One or two focal stenoses, each less than Lm long, at the tibial trifurcation
4. Short tibial or peroneal stenosis in conjunction with femoropopliteal PTA
TASC Type C infrapopliteallesions:
5. Stenoses 1-4 em in length
6. Occlusions 1-2 em in length of the tibial or peroneal vessels
7. Extensive stenoses of the tibial trifurcation
TASC Type D infrapopliteal lesions:
8. Tibial or peroneal occlusions longer than 2 ern
9. Diffusely diseased tibial or peroneal vessels
The choice of intervention, between open surgery and an endovascular procedure, can be diffi-
cult, often weighing risks to life and limb against each other in an attempt to save both. There
are risks to limb and life involved in any attempted revascularization procedure, particularly in
some difficult surgical bypasses, but patients with eLI have complex lesions not suitable for
endovascular treatment, and amputation has the same risk. Accurately predicting the result of a
particular revascularization in an individual is difficult based on available literature. The assess-
ment of chances of success in an individual case would be better based on the audited results
obtained in the relevant institution rather than published results from other centers (see p S261).
It is important to develop guidelines regarding the likelihood of success below which a recon-
struction should not attempted.
References
I. Hunink MG, Wnng JR,Donaldson MC, Meyerovitz MF, de Vries J, Harrington DJ>. Revascularization for fernoropopliteal disease:
a decision and cost-effectiveness analysis. JAMA 1995;274: 165-171.
2. Hunink MG, Wong [B, Donaldson MC, Meyerovitz MF, Harrington DP. Patency results of percutaneous and surgical rcvascular-
izations for femoropopliteal arterial disease. Med Decis Making 1994;14:71-81.
3. Wilson SE, Wolf GL, Cross AI'. Percutaneous transluminal angioplasry vs. operation for peripheral arteriosclerosis: report of a
prospective randomized trial in a selected group of patients. J Vasc Surg 1989;9: 1-9.
